• Home
  • NEW DAY MEDICINE
  • 2 (52) 2023
  • 11 -2 (52) 2023 — Shagazatova B.Kh., Rakhimova S.Kh. — IMPACT OF BARITARY SURGERY ON THE TREATMENT OF NON-ALKHOLIC FATTY LIVER DISEASE

11 -2 (52) 2023 — Shagazatova B.Kh., Rakhimova S.Kh. — IMPACT OF BARITARY SURGERY ON THE TREATMENT OF NON-ALKHOLIC FATTY LIVER DISEASE

IMPACT OF BARITARY SURGERY ON THE TREATMENT OF NON-ALKHOLIC FATTY LIVER DISEASE

Shagazatova B.Kh., Tashkent Medical Academy

Rakhimova S.Kh. Tashkent Medical Academy

Resume

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and in Asia. The incidence of NAFLD has been reported to range from 65% to 95% in patients undergoing bariatric surgery. The spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) to fibrosis and cirrhosis. Treatment strategies include lifestyle modification, pharmacotherapy, and bariatric surgery. Bariatric surgery has shown promising results worldwide and in Asian patients. . According to Asian scientists, there is a significant improvement in NAFLD after both restrictive and malabsorptive procedures. The data show the disappearance of all signs of NAFLD, NASH and fibrosis after bariatric surgery.

Key words: non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); bariatric surgery metabolic surgery.

First page

62

Last page

68

For citation: Shagazatova B.Kh., Rakhimova S.Kh. – IMPACT OF BARITARY SURGERY ON THE TREATMENT OF NON-ALKHOLIC FATTY LIVER DISEASE //New Day in Medicine 2(52)2023 62-68 https://clck.ru/33X3yG

LIST OF REFERENCES:

  1. Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. //J. Hepatol. 2013; 58:593–608.
  2. Golabi P., Otgonsuren M., de Avila L., Sayiner M., Rafiq N., Younossi Z.M. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) Medicine. 2018; 97: e0214.
  3. Golabi P., Otgonsuren M., de Avila L., Sayiner M., Rafiq N., Younossi Z.M. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) Medicine. 2018; 97:e0214.
  4. Cholongitas E., Pavlopoulou I., Papatheodoridi M., Markakis G.E., Bouras E., Haidich A.B., Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis. //Ann. Gastroenterol. 2021; 34:404–414.
  5. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. //J. Hepatol. 2016; 64:1388–1402. doi: 10.1016/j.jhep.2015.11.004.
  6. Della Pepa G., Russo M., Vitale M., Carli F., Vetrani C., Masulli M., Riccardi G., Vaccaro O., Gastaldelli A., Rivellese A.A., et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. //Diabetes Res. Clin. Pract. 2021; 178:108984.
  7.  Bril F., Kalavalapalli S., Clark V.C., Lomonaco R., Soldevila-Pico C., Liu I.C., Orsak B., Tio F., Cusi K. Response to Pioglitazone in Patients with Nonalcoholic Steatohepatitis with vs without Type 2 Diabetes. //Clin. Gastroenterol. Hepatol. 2018;16:558–566.e2
  8.  Armstrong M.J., Gaunt P., Aithal G.P., Parker R., Barton D.J., Hull D. Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicenter, double-blinded, randomized, placebo-controlled phase II trial. //J. Hepatol. 2015; 62:S187. doi: 10.1016/S0168-8278(15)30002-7
  9. Yang M., Ma X., Xuan X., Deng H., Chen Q., Yuan L. Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. //Front. Pharmacol. 2020; 11:432. 
  10. Tang W., Xu Q., Hong T., Tong G., Feng W., Shen S., Bi Y., Zhu D. Comparative efficacy of anti-diabetic agents on NAFLD in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized and non-randomized studies. //Diabetes Metab. Res. Rev. 2016;32:200–216
  11. Brandt A., Hernández-Arriaga A., Kehm R., Sánchez V., Jin J.C., Nier A., Baumann A., Camarinha-Silva A., Bergheim I. Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. //Sci. Rep. 2019; 9:6668.
  12. Perumpail B.J., Li A.A., John N., Sallam S., Shah N.D., Kwong W., Cholankeril G., Kim D., Ahmed A. The Role of Vitamin E in the Treatment of NAFLD. //Diseases. 2018; 6:86. 
  13. Pan C.S., Stanley T.L. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front. //Endocrinol. 2020;11:70
  14. Venetsanaki V., Karabouta Z., Polyzos S.A. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. //Eur. J. Pharmacol. 2019;15:172661
  15. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Chalasani N., Dasarathy S., Diehl A.M., Hameed B., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicenter, randomized, placebo-controlled trial. //Lancet. 2015;385:956–965
  16. Loomba R., Noureddin M., Kowdley K.V., Kohli A., Sheikh A., Neff G., Bhandari B.R., Gunn N., Caldwell S.H., Goodman Z., et al. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. //Hepatology. 2021;73:625–643
  17. Harrison S.A., Abdelmalek M.F., Caldwell S., Shiffman M.L., Diehl A.M., Ghalib R., Lawitz E.J., Rockey D.C., Schall R.A., Jia C., et al. Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. //Gastroenterology. 2018;155:1140–1153
  18. Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H., Diehl A.M., Djedjos C.S., Han L., Myers R.P., et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. //Hepatology. 2018; 67:549–559.
  19. Sutanto A., Wungu C.D.K., Susilo H., Sutanto H. Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis. //Nutrients. 2021;13:3568
  20. Klein S., Mittendorfer B., Eagon J.C., Patterson B., Grant L., Feirt N., Seki E., Brenner D., Korenblat K., McCrea J. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. //Gastroenterology. 2006; 130:1564–1572. 

file

download